Mayo Clinic-backed Nucleus RadioPharma raises $56M in Series A to boost CDMO services
Nucleus RadioPharma is making a splash with an oversubscribed $56 million Series A to prop up the CDMO’s manufacturing capacity, with a Rochester, MN site expected to be completed by the end of the year. The raise will also be used to fund the construction of two regional hubs, as well as increase its research and supply chain capabilities.
“We could have gone larger, we just decided to stop,” Nucleus CEO Charles Conroy told Endpoints News in an interview. “The science is very well-proven — the support structure is just not in place to make sure we can get it to patients,” he added.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
